These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586 [No Abstract] [Full Text] [Related]
5. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease. Andrews CJ; Somerville B Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384 [No Abstract] [Full Text] [Related]
7. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):31-5. PubMed ID: 4924342 [No Abstract] [Full Text] [Related]
8. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
9. L-dopa therapy in Parkinson's disease. Lipman IJ Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138 [No Abstract] [Full Text] [Related]
10. A double-blind controlled study of MK-486 in Parkinson's disease. Schwartz AM; Olanow CW; Spencer A Trans Am Neurol Assoc; 1973; 98():301-3. PubMed ID: 4594189 [No Abstract] [Full Text] [Related]
11. [L-Dopa therapy in Parkinson's disease. A double-blind study]. Worm-Petersen J; Dupont E; Mikkelsen B Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651 [No Abstract] [Full Text] [Related]
13. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor]. Siegfried J; Klaiber R; Perret E; Ziegler WH Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342 [No Abstract] [Full Text] [Related]
14. Levodopa in parkinson's disease--Australian collaborative trial. Selby G Med J Aust; 1973 Mar; 1(12):577-85. PubMed ID: 4700544 [No Abstract] [Full Text] [Related]
15. [Clinical study of L-dopa in Parkinson's disease]. Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350 [No Abstract] [Full Text] [Related]
16. Psychiatric changes in patients treated with levodopa. I. The clinical experiment. Knopp W Neurology; 1970 Dec; 20(12):Suppl:23-30. PubMed ID: 4921585 [No Abstract] [Full Text] [Related]
17. [Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]. Schneider E; Fischer PA; Clemens R; Balzereit F; Fünfgeld EW; Haase HJ Dtsch Med Wochenschr; 1984 Jun; 109(25):987-90. PubMed ID: 6734455 [TBL] [Abstract][Full Text] [Related]
18. [Management of Parkinson's syndrome using levadopa. Results of a long-term study]. Wälzholz U Dtsch Med Wochenschr; 1972 Apr; 97(17):686 passim. PubMed ID: 4554502 [No Abstract] [Full Text] [Related]
19. [Piribedil in the treatment of Parkinson disease (author's transl)]. Nardini M; Sciannandrone R; Fieschi C; De Simone G Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998 [TBL] [Abstract][Full Text] [Related]
20. Effect of fusaric acid in Parkinson's disease. Herskovits E; Figueroa Gacitua E Medicina (B Aires); 1973; 33(1):51-8. PubMed ID: 4573120 [No Abstract] [Full Text] [Related] [Next] [New Search]